Abstract: One aspect of the present invention relates to heterocyclic compounds. A second aspect of the present invention relates to the use of the heterocyclic compounds as ligands for various mammalian cellular receptors, including dopamine, serotonin, or norepinephrine transporters. The compounds of the present invention will find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to addiction, anxiety, depression, sexual dysfunction, hypertension, migraine, Alzheimer's disease, obesity, emesis, psychosis, schizophrenia, Parkinson's disease, inflammatory pain, neuropathic pain, Lesche-Nyhane disease, Wilson's disease, and Tourette's syndrome. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the heterocyclic compounds, and the screening of those libraries for biological activity, e.g., in assays based on dopamine transporters.

Abstract: The compounds of the subject invention have a structure according to formula I: wherein each of the substituents is given the definition as set forth in the specification and claims, or a salt or hydrate form thereof.

Abstract: Compounds with antiplatelet aggregation and anticoagulant characteristics for the treatment of cardiovascular, cerebrovascular, and cardiovascular related diseases and symptoms, are described. The methods are directed to administering pharmaceutical compositions comprising aryl sulfonic pyridoxine and/or substituted pyridoxine analogs.

Abstract: A method for the inhibition of the binding of ?4?1 integrin to its receptors, for example VCAM-1 (vascular cell adhesion molecule-1) and fibronectin; compounds that inhibit this binding; pharmaceutically active compositions comprising such compounds; and to the use of such compounds either a above, or in formulations for the control or prevention of diseases states in which ?4?1 is involved.

Abstract: Nitro-oxyderivative compounds or salts thereof having the following general formula (I): A-(B)b0-(C)o0-N02 wherein: c0 is an integer and is 0 or 1, b0 is an integer and is 0 or 1, A=R-TI-, wherein R is the radical of an analgesic drug for the chronic pain, in particular for the neuropathic pain; B is such that its precursor is selected from aminoacids, hydroxyacids, polyalcohols, compounds containing at least one acid function; C is a bivalent radical containing an aliphatic, heterocyclic or aromatic radical.

Abstract: This invention is directed to a compound of the formula Ia or Ib, as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula I, a method of treatment of a disorder or condition that may be treated by antagonizing histamine H3 receptors, the method comprising administering to a mammal in need of such treatment a compound of formula I as described above, and a method of treatment of a disorder or condition selected from the group consisting of depression, mood disorders, schizophrenia, anxiety disorders, Alzheimer's disease, attention-deficit disorder (ADD), attention-deficit hyperactivity disorder (ADHD), psychotic disorders, sleep disorders, obesity, dizziness, epilepsy, motion sickness, respiratory diseases, allergy, allergy-induced airway responses, allergic rhinitis, nasal congestion, allergic congestion, congestion, hypotension, cardiovascular disease, diseases of the GI tract, hyper and hypo motility and acidic secretion of the gastro-i

Abstract: The present invention relates to compounds of the general formula (I) and salts and physiologically functional derivatives thereof, wherein R1 is independently hydrogen; alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, haloalkyloxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl or substituted arylalkyl; R2 is independently —NR3R4, R3 is independently alkyl, cycloalkyl, alkoxy, alkylamine, —OH, —SH, alkylthio, hydroxyalkyl, haloalkyl, haloalkyloxy, aryl or heteroaryl, R4 is independently alkyl, cycloalkyl, alkoxy, alkylamine, alkylthio, hydroxyalkyl, haloalkyl, haloalkyloxy, aryl or heteroaryl; R5 is independently H, COR6, CO2R6, SOR6, SO3R6, alkyl, cycloalkyl, alkoxy, —NH2, alkylamine, —NR7COR6, halogen, —OH, —SH, alkylthio, hydroxyalkyl, haloalkyl, haloalkyloxy, aryl or heteroaryl; R6 is independently H, alkyl, cycloalkyl, —NH2, alkylamine, aryl or heteroaryl; R7 is independently H, alkyl, cycloalkyl, alkoxy, —OH, —SH, alkylthio, hydroxyalkyl, aryl, or heteroaryl; p is 0, or 1;

Abstract: Therapeutic applications, such as prevention, treatment and supplementation, for the use of novel and other thiolatocobalamins to protect human cells against the effects of oxidative stress. In particular, this invention relates to the use of a novel synthetic thiolatocobalamin, N-acetyl-L-cysteinylcobalamin (NACCbl) to protect animal cells against oxidative stress damage. This invention also relates to the use of thiolatocobalamins, such as NACCbl, in lieu of current, commercially available forms of vitamin B12 for the treatment and prevention of conditions associated with oxidative stress damage and for dietary supplementation.

Abstract: This invention relates to compounds that are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial. The compounds are of the general formula (I) wherein A and B are further defined in the application.

Abstract: Remedies/preventives for hormone-independent cancer, hormone-independent cancer cell proliferation inhibitors, apoptosis inducers for cancer cells, etc. each containing a compound having an angiotensin II antagonism, its prodrug or a salt thereof. Thus, excellent anticancer agents are provided.

Abstract: Disclosed herein are antifungal triazole derivatives or pharmaceutically acceptable salts thereof, a preparation method thereof, and a pharmaceutical composition comprising the same.

Abstract: Methods are provided for treating or prophylactically preventing metabolic disorders in humans without causing, promoting, or aggravating fluid retention, peripheral edema, pulmonary edema, or congestive heart failure, by administration of a therapeutically effective amount of a compound sufficient to partially or fully activate peroxisome proliferator activated receptors (PPARs) and partially or fully inhibit, antagonize or block the activity of angiotensin II type 1 receptors. Metabolic disorders that can be treated or prevented include but are not limited to type 2 diabetes, the metabolic syndrome, prediabetes, and other insulin resistance syndromes.

Abstract: The present invention relates to compounds of formula wherein R1, R2, X, Y and Ar are as defined herein and to their pharmaceutically active salts, with the exclusion of the racemic compound 4-benzyl-4,5-dihydro-1H-imidazole or its tautomer (CAS 131548-83-9).

Abstract: Compounds are provided which are activators of the enzyme glucokinase and thus are useful in treating diabetes and related diseases, which compounds have the structure where Q is and R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein or a pharmaceutically acceptable salt thereof. A method for treating diabetes and related diseases employing the above compounds is also provided.

Abstract: The present invention is directed to the treatment of skin erythema as exhibited in rosacea and other conditions characterized by increased erythema (redness) of the skin. These conditions exhibit dilation of blood vessels due to a cutaneous vascular hyper-reactivity. In particular, the present invention is directed to a novel composition and method for the treatment of skin erythema using ?1-adrenergic receptor (?1-adrenoceptor) agonists incorporated into cosmetic, pharmacological or dermatological compositions for topical application to the skin.

Abstract: Provided herein is a new form of 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathin 10,10-dioxide, which demonstrates higher stability relative to other forms of 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin-10,10-dioxide. In particular, this new form affords less dosage critical administration of 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathin 10,10-dioxide relative to other forms. The new solid form of 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin-10,10-dioxide has been determined and is provided herein. This new solid form of 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin-10,10-dioxide can be characterized by any of a number of its properties, including, but not limited to, melting point, differential scanning calorimetry, infrared spectroscopic spectrum or portions thereof, solubility, methods and conditions under which this form is prepared, and/or precipitated from solution, and, when in crystalline form, the crystalline form can be characterized according to the diffraction pattern or portions thereof.

Abstract: The present invention relates to polymer-modified quinone-containing and carbonyl-containing therapeutic agents, including polymer-modified ?-lapachone compounds, and methods of treating cancer by administering the polymer-modified therapeutic agents to a subject. Polymer-modification of therapeutic agents, such as ?-lapachone compounds, provides effective transport of polymer-modified therapeutic agents to tumor cells or tumor tissues by exploiting the EPR effect in tumor tissues.

Abstract: Disclosed is a stable aqueous formulation of a platin derivative, particularly oxaliplatin. The selected stabilizing additive is effective even in very small concentrations.

Abstract: The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR modulators to treat or inhibit the progression of, for example, dyslipidemia.

Abstract: This invention provides new lipoxin analogs, compositions containing analogs, and methods of using these compounds and compositions for treating and preventing oral inflammation, including gingivitis, periodontitis, and other forms of periodontal disease. The invention also provides for methods of treating and preventing oral inflammation, including gingivitis, periodontitis, and other forms of periodontal disease with compositions containing COX-2 inhibitors. Further, the invention provides methods for preventing systemic diseases beyond theoral cavity that are related to periodontal disease using the composition containing lipoxin analogs, COX-2 inhibitors, or both.

Abstract: Described is a method and a composition for preparing wood, to its use and to the wooden product obtained by the method. The method and the composition use liquid or water-soluble organic ammonium carboxylate of formula (1): [NR1R2R3R4]+n[R5(COO)n]?n (1), in which R1, R2 and R3 are selected from hydrogen, substituted alkyls containing 1-6 carbon atoms and unsubstituted alkyls containing 1-6 carbon atoms, R4 is a substituted alkyl or an unsubstituted alkyl containing 1-6 carbon atoms, R5 is hydrogen, a substituted hydrocarbyl containing 1-6 carbon atoms or an unsubstituted hydrocarbyl containing 1-6 carbon atoms, and n is an integer 1-6. This substance has good absorption into and high retention in wood.

Abstract: A fine particle dispersant containing at least one member selected from the group consisting of ester compounds of the following general formula (I) of ditrimethylolpropane and a fatty acid(s), polycondensates of ditrimethylolpropane and a polyvalent carboxylic acid(s), polycondensates of the ester compound of the following general formula (I) and the polyvalent carboxylic acid(s), polycondensates of an ester compound of ditrimethylolpropane and the polyvalent carboxylic acid(s) and the fatty acid(s), and polycondensates of ditrimethylolpropane, the fatty acid(s) and the polyvalent carboxylic acid(s). wherein R1 to R4 each independently represent a hydrogen atom or a fatty acid residue, with the proviso that at least one of them is a hydrogen atom. This fine particle dispersant is excellent in fine particle dispersibility and the properties (smell and color) thereof are scarcely deteriorated in heat stability tests.

Abstract: A composition and method for improving skin appearance by reducing skin redness and symptoms associated with skin inflammation, irritation and skin aging by topically treating skin is disclosed. In this composition and method, an active material having the formula given below is applied to the patient at the site of said condition: wherein R1 is selected from —OH and C1-C3 alkyl OH; and R2, R3, R4, R5 and R6 are independently selected from —H, —OH, C1-C6 alkyl, and C3-C6 cycloalkyl. The active material should contain no more than five —OH groups. Preferred active materials include 1,2-cyclohexanediol, 1,3-cyclohexanediol, 1,4-cyclohexanediol, 1,2,3-cyclohexanetriol, 1,3,5-cyclohexanetriol, and mixtures of those materials. A method of maintaining healthy hair and reducing hair loss using these actives is also disclosed.

Abstract: The present invention provides a method for treating cancer in a mammal comprising contacting the cancer cells with a compound which is a apogossypol, derivative.

Abstract: The invention relates to a method for producing an aerogel that contains a filler and has an extremely low thermal conductivity. The aerogel moulded body contains an inorganic filler with a thermal conductivity of up to 0.5 Wm?1K?1.

Abstract: A method of treating off-gas from a Fischer-Tropsch reaction comprises recovering the off-gas and hydrogenating a portion of the olefins present in the off-gas and converting a portion of the carbon monoxide present in the off-gas to carbon dioxide or methane. The treated off-gas is then fed to a hydrogen manufacturing unit such as a steam reformer to form hydrogen that can be used elsewhere in the process.

Abstract: A method for manufacturing a recycled polycarbonate raw material for a flame retardant resin composition from discarded and/or recovered optical discs using a polycarbonate resin as a substrate material, and includes (a) a step to identify if 2,2-bis(4-hydroxyphenyl)propane as a divalent phenol of the polycarbonate resin raw material is polymerized as the sole raw material in the polycarbonate resin as the substrate material of the discarded and/or recovered optical discs and (b) a step to remove impurities by a chemical treatment by separating only the discarded and/or recovered optical discs, wherein the polycarbonate resin is identified as polymerized by using 2,2-bis(4-hydroxyphenyl)propane as the sole raw material.

Abstract: Olefin polymer-based, durable, open-cell foam compositions, structures and articles derived from same; methods for preparation of such foams; and use of the dry durable foams in various applications are disclosed. Further described is use of the foams and structures and articles made of same in absorption, filtration, insulation, cushioning and backing applications, and in particular for odor removal, hygiene and medical applications due to, among other properties, good absorption capabilities, softness and/or flexibility of the foams and their recyclable nature.

Abstract: The invention relates to a flame-retardant resin formulation comprising respectively at least one flame-retardant component, one alkali-soluble component, one polymerizable monomer, one photoinitiator, and one epoxy component, which comprises, as flame-retardant component, a phosphinic salt of the formula (I), in which R1 and R2 are identical or different and, independently of one another, are C1-C6-alkyl, linear or branched, and/or aryl; M is Mg, Ca, Al, Sb, Sn, Ge, Ti, Zn, Fe, Zr, Ce, Bi, Sr, Mn, Li, Na, K, and/or a protonated nitrogen base, and m is from 1 to 4. This novel flame-retardant resin formulation is preferably used as solder resist.

Abstract: A radiation curable phase change ink comprising a white colorant; a colorant dispersant; and an ink vehicle comprising at least one curable monomer; at least one gellant; optionally at least one photoinitiator; optionally at least one stabilizer; and optionally at least one wax.

Abstract: Dental impression masses are described, which contain selected curable polymer systems and a mixture of a silicon-containing non-ionic surfactant that has at least one (poly)alkylene oxide group and a molecular mass of less than 6000 g/mol, and of a non-ionic fluorosurfactant containing at least one partially fluoridated or perfluoridated hydrocarbon group that is connected with a (poly)alkylene oxide group, a hydrocarbon group, an aliphatic polyhydroxy group, or heterocyclic group that contains nitrogen, by way of an oxygen atom, an amino group, a keto group, a carboxylic acid ester group, a phosphoric acid ester group, a carboxylic acid amide group and/or a phosphoric acid amide group, or of a non-ionic fluorosurfactant that has at least one partially fluoridated or perfluoridated hydrocarbon radical and at least one amino oxide radical.

Abstract: The invention relates to a biodegradable resin composition containing a biodegradable resin, a plasticizer and a crystal nucleus agent, the plasticizer being a compound containing two or more ester groups in the molecule thereof, wherein at least one alcohol component constituting the ester contains an alkylene oxide having 2 to 3 carbon atoms, added in the average amount of 0.

Abstract: Disclosed herein are inks including an aqueous vehicle; at least one encapsulant-dispersed pigment; and at least one block copolymer binder dispersed throughout the aqueous vehicle and having Structure I and comprising a hydrophobic block (A) and a hydrophilic block (B);

Abstract: The invention provides a recording ink containing a colorant, a wetting agent, a surfactant, a penetrating agent, and water, wherein when the specified moisture evaporation rate of the recording ink is less than 30% the specified viscosity elevating rate of the recording ink is 10 or less; when the moisture evaporation rate is 30% to 50%, there is a point at which the viscosity elevating rate is more than 500; and when the moisture evaporation rate is less than 30%, the average particle diameter of the colorant in the recording ink is two times or less the initial average particle diameter of the colorant before the moisture evaporation test of the recording ink.

Abstract: A reversible viscosity reducing polymer is provided that has a crosslinkage between subunits inclusive of a single Diels-Alder Such a reversible viscosity reducing polymer is particularly well suited as a matrix material for a heterogeneous propellant. A process for forming a reversible viscosity reducing polymer inclusive of a single Diels-Alder linkage includes reacting a native crosslinkable moiety with a crosslinker moiety having a Diels-Alder reactive moiety of a diene or dienophile to form a Diels-Alder reactive moiety capped polymer subunit. The Diels-Alder reactive moiety capped polymer subunit is then exposed to a Diels-Alder reactant inclusive of a complementary Diels-Alder reactive moiety where the reactant also includes at least one conventional crosslinkable moiety to form a crosslinkable moiety capped polymer subunit. Reaction of the crosslinkable moiety capped polymer subunit is then reacted with a conventional multifunctional crosslinking agent.

Abstract: The present invention relates to a microencapsulated pigment in which pigment particles having cationic groups on their surfaces are coated with a polymer having repeating structural units derived from an anionic polymerizable surfactant having at least an anionic group, a hydrophobic group and a polymerizable group, and a microencapsulated pigment in which pigment particles having anionic groups on their surfaces are coated with a polymer having repeating structural units derived from a cationic polymerizable surfactant having a cationic group, a hydrophobic group and a polymerizable group. Further, the invention relates to a process for producing the microencapsulated pigment, an aqueous dispersion containing the microencapsulated pigment, and an ink jet recording ink containing the aqueous dispersion.

Abstract: A veneer composition that includes a mixture of at least one of an acrylic emulsion and one or more hard resins and also includes at least about 60% by volume of translucent, uniformly spherical, non-resin, absorbent beads of at least one of acrylic and polypropylene.

Abstract: A method of preparing a styrene polymer-silica nanocomposite is disclosed. One embodiment of the method includes polymerizing about 100 parts by weight of a monomer mixture including about 50 to about 80% by weight of an aromatic monomer an about 20 to about 50% by weight of a vinyl cyanide monomer with about 0.5 to about 30 parts by weight of a colloidal silica dispersed in a first organic solvent.

Abstract: A preparation method of small particle-sized polybutadiene latex used for the production of ABS is disclosed, which includes putting components comprising 34.00-45.00% by weight of the butadiene, 0-6.0% by weight of the second monomer, 52.11-63.13% by weight of the desalinized water, 0.12-0.22% by weight of the mercaptan(TDM), 0.80-2.60% by weight of the emulsifiers composed of potassium abietate and potassium oleate, into the same polymerization reactor, then heating the mixture of the components and stirring the same at a temperature range of 60-75° C. The reaction lasts for 9-12 hours and the conversion is higher than 97%. The method has the advantages such as higher conversion, shorter reaction period and lower latex viscosity. During the first stage of the reaction, more heat is released by increasing the reaction rate. When the conversion reaches 40-80%, the heat release rate of intermediate stage is depressed by decreasing the reaction temperature.

Abstract: The present invention relates to a solvent-free polyurethane-based artificial leather having the texture of human skin, and particularly to artificial leather comprising soy protein isolate and solvent-free polyurethane resin, where the use of soy protein isolate provides a higher water content than that of the conventional artificial leather to improve sensitivity properties such as tactile sensation and the use of the solvent-free polyurethane resin provides higher heat resistance and better mechanical properties than those of the conventional artificial leather, without using an organic solvent, thereby enabling to maintain clean indoor air.

Abstract: A compound of Formula (I): wherein R3 is an aromatic functionality selected from the group consisting of Formula II and Formula III: and wherein R1, R2, R5, R6, R7, R9, and R10 are independently selected from the group consisting of an aliphatic functionality having 1 to 6 carbon atoms, an aromatic functionality having 3 to 20 carbon atoms, a cycloaliphatic functionality having 3 to 20 carbon atoms, a hydroxy group, a halogen group, and a cyano group; R4 is an aliphatic functionality having 1 to 6 carbon atoms; R8 is an aliphatic functionality having 1 to 6 carbon atoms; “n” has a value of 0 to 4; “m” has a value of 0 to 2; “p” has a value of 0 to 2; “u” has a value of 0 to 2; “q” has a value of 0 to 3; “t” has a value of 0 to 4; and “r” has a value of 0 to 5.

Abstract: A composition comprises 20 to 80 wt. % of a polyester component comprising a modified polybutylene terephthalate random copolymer derived from a polyethylene terephthalate component selected from polyethylene terephthalate and polyethylene terephthalate copolymers and having at least one residue derived from the polyethylene terephthalate component; from 5 to 35 wt. % of a flame retardant phosphinate (I) or (II) (R1)(R2)(PO)—O]?mMm+??(I) [(O—POR1)(R3)(POR2—O)]2?nMm+x??(II), and/or a flame retardant polymer thereof, wherein R1 and R2 are independently are H, C1-C6-alkyl, or C6-C10-aryl; R3 is C1-C10, alkylene, C6-C10-arylene, -alkylarylene or -arylalkylene; M is an alkaline earth metal, alkali metal, Al, Ti, Zn, Fe, or boron; m is 1, 2, 3 or 4; n is 1, 2, or 3; and x is 1 or 2; 1 to 25 wt. % of a melamine polyphosphate, melamine cyanurate, melamine pyrophosphate, and/or melamine phosphate; and more than 0 to 25 wt. % of a polyetherimide.

Abstract: A thermoplastic composition comprises a polycarbonate, and an aromatic sulfonate compound of formula (Y)m—Ar—(Z—S(O)2—X)n wherein each X is independently a substituted or unsubstituted C1-C20 alkyl, substituted or unsubstituted C1-C20 arylalkyl, substituted or unsubstituted C6-C20 aryl, or substituted or unsubstituted C7-C40 alkylaryl; Z is —O—, or substituted or unsubstituted —(O—C1-20—)w—O—, wherein w is 1 to 20; Ar is a C6-C62 aromatic group; m is 0-3 and n is 3-6; and each Y is independently C1-C20 alkyl, substituted C1-C20 alkyl, C6-C20 aryl, C1-C8 alkyl-substituted C6-C20 aryl, halogen, nitro, C1-C20 alkoxycarbonyl, C1-C20 alkoxy, or C1-C20 acyl, and further wherein a molded article having a thickness of 3.2±0.

Abstract: Coating compositions containing coalescents and a latex polymer, wherein the coalescent has a volatile organic content of less than about 50% and is dispersible in the coating composition.

Abstract: Plastisols are provided which are effective for providing a foamed composition having an improved color. The plastisol includes a dispersed phase and a liquid phase. The dispersed phase includes an organic polymer and the liquid phase includes a plasticizer for said polymer. The plasticizer utilized has a hydroxyl number of about 30 or greater, and an acidity of not less than about 0.1% as benzoic acid.

Abstract: Method for making a mixture used in the production of a polytetrafluoroethylene (PTFE) membrane including porous inorganic materials. The mixture includes PTFE resin, a lubricating agent, and a porous inorganic material. The mixture may be further processed to form a PTFE membrane.

Abstract: The invention relates to absorptive, crosslinked polymers which are based on partly neutralized, monoethylenically unsaturated monomer carrying acid groups wherein the absorptive crosslinked polymer may be coated with a thermoplastic polymer, and have improved properties, in particular in respect of their capacity for transportation of liquids in the swollen state, and which has a high gel bed permeability and compatibility to affix to a thermoplastic material.

Abstract: The invention provides a method for the preparation of a suspension of de-agglomerated carbon nanotubes, comprising mixing agglomerated carbon nanotubes with a block copolymer. Further, a powder of de-agglomerated carbon nanotubes is provided, that can be easily redispersed to obtain a suspension of untangled carbon nanotubes. The invention also relates to the use of the provided materials in the preparation of composites, and in electronics.

Abstract: A polyamic acid composition, containing polyamic acid and polyaniline particles, with reduced fluctuation of properties after production; a preparation method for the same; a polyimide resin having reduced fluctuation of resistance properties, superior mechanical properties and superior surface smoothness; a semiconductive member, and an image-forming apparatus having the semiconductive member as a belt. A polyamic acid composition, including a polyamic acid, polyaniline particles having a fibrous region with an aspect ratio of between approximately 1 to approximately 100 or less, a dopant, and a solvent.

Abstract: This invention relates to an adhesive composition comprising a functionalized random propylene polymer (FRPP) having at least 0.1 wt % of a functional group, a heat of fusion of between 0.5 and 70 J/g, and an mm triad tacticity index of at least 75%, where the adhesive has a T-Peel adhesion on a polar substrate at 20° C. of at least 175 N/m (1 lb/in) and a T-Peel adhesion on a non-polar substrate at 20° C. of at least 175 N/m (1 lb/in) where the polarity of the polar substrate is at least 0.10 units higher than the polarity of the non-polar substrate. Methods to produce the adhesive and articles comprising the adhesive are also disclosed.